PM54 (ecubectedin)
Solid Tumors
Phase 1Active
Key Facts
About Pharma Mar
Pharma Mar's mission is to discover and develop novel cancer therapies derived from the chemical diversity of marine organisms. Its key achievement is the successful global commercialization of Yondelis® (trabectedin), a first-in-class marine-derived drug approved for soft tissue sarcoma and ovarian cancer, validating its unique platform. The company's strategy focuses on leveraging its proprietary marine biology and chemistry expertise to advance a deep pipeline of drug candidates, while exploring new indications and combinations for its existing assets. This integrated approach, from discovery to manufacturing and commercialization, aims to deliver long-term growth in the oncology market.
View full company profileTherapeutic Areas
Other Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| APVO603 | Aptevo Therapeutics | Preclinical |
| APVO711 | Aptevo Therapeutics | Preclinical |
| Platform-derived Immunotherapy | GenCirq | Pre-clinical |
| SP-2-225 | Shuttle Pharmaceuticals | Preclinical |
| SP-1-161 | Shuttle Pharmaceuticals | Preclinical |
| HBM1020 | Harbour BioMed | Phase 1 |
| HBM7022 | Harbour BioMed | Phase 1 |
| HBM9033 | Harbour BioMed | Discovery |
| Undisclosed Whole Cell Vaccine Program(s) | Neuvogen | Pre-clinical |
| SY-5609 | Syros Pharmaceuticals | Phase 1/2 |
| Not Specified (TCR Therapy) | T-Cure Bioscience | Phase 1 |
| B7-H3 Program | Ocean Biomedical | Discovery |